Navigation Links
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
Date:11/11/2013

I/II dose-escalation trial designed to assess the safety and preliminary efficacy of our lead product candidate, VAL-083, for the treatment of GBM.  

The results reported to date have shown promising drug activity and we believe that VAL-083 represents a potential new treatment option for brain tumor patients who have failed or are unlikely to benefit from today's standard of care.  More than half of patients fail the currently approved treatments.

The goal of our current clinical trial is to establish the optimal VAL-083 dosing regimen for both safety and efficacy in a U.S.-based GBM patient population. This dose would then be advanced into a Phase III GBM registration study, which we expect to commence in mid-2014 . During the past quarter, the U.S. Food and Drug Administration (FDA) undertook a detailed safety review of the Phase I/II trial and allowed us to accelerate our dose escalation program.  While this modification is unlikely to shorten the trial due to the length of our discussions with the FDA throughout this review, we should realize significant cost savings as fewer patients will be exposed to sub-optimal doses within the escalation study. We will present additional data from the ongoing Phase I/II trial during the Society for NeuroOncology (SNO) Annual Meeting on Friday November 22, 2013. 

We Are Strengthening Our Intellectual Property Portfolio
We have filed a broad portfolio of new patent applications to protect our intellectual property. Our patent applications claim compositions and methods related to the use of VAL-083 and related compounds as well as methods of synthesis and quality controls for the manufacturing process of VAL-083. In addition to our patent portfolio, VAL-083 has been granted Orphan Drug protection for the treatment of glioma, including GBM, in both the U.S. and Europe.  The orphan drug designation provides VAL-0
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
3. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
4. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
8. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Nov. 22, 2011  Colorado Drug Card, in partnership with ... has agreed to be the "Preferred Pharmacy" for the ... to process prescriptions through Colorado Drug Card. Coloradans can ... pharmacist to process their prescription through the Colorado Drug ...
... Nov. 22, 2011 Omeros Corporation (NASDAQ: ... to discovering, developing and commercializing products targeting inflammation, ... today announced that Gregory A. Demopulos, M.D., chairman ... at the 23rd Annual Piper Jaffray Health Care ...
Cached Medicine Technology:
(Date:8/30/2014)... Beach, Calif. (PRWEB) August 30, 2014 Insomnia ... Francis helps listeners understand how they unknowingly developed insomnia and ... have restful nights during. Tune in to the show ... The show airs live on August 30, and will ... more information on programming, go to DrCarolFrancisTalkRadio.com. , ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk along ... Wetumpka, Ala. "In order to help her be able to ... up with a way for her to use her crutches ... patent-pending Deezers to allow crutches to be used on uneven ... or canes at the beach. The device reduces the risk ...
(Date:8/30/2014)... WA (PRWEB) August 30, 2014 One of ... this era is the gluten-free diet. Originally meant for sufferers ... become a catchall for people who are looking to get ... However, not only is this kind of information erroneous, it ... health problems because of a drastic change in their ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... Unique off-label marketing case results in $425M ... government,s investigation,into Cephalon Inc.,s illegal marketing practices ... plea by the pharmaceutical company began,in January ... Ohio., The sales representative, Bruce Boise, ...
... Bear Bryant,Awards committee of the American Heart Association has ... has been named the,2009 winner of its, Lifetime Achievement ... Award at the Paul Bear,Bryant College Football Coaching Awards ... in Houston. The award recognizes excellence in,coaching on and ...
... pharmacy chain Walgreens has paid the United ... resolve allegations of falsely billing,the Medicaid program, ... submitted claims to Medicaid agencies in four ... both by Medicaid and by,private third-party insurance. ...
... More and more cancer patients are,looking for treatment ... of,life during difficult treatment regimens., ... at:, http://media.medialink.com/WebNR.aspx?story=35774 ) Philips Research is developing ... the effectiveness and reduce the side,effects of chemotherapy ...
... study also finds too many clinicians still using ... -- In children and teens, individual and group ... stress disorder (PTSD) and other trauma symptoms, say ... studies on the subject. , However, despite the ...
... it a “carrier of choice” for many in the medical device ... ... -- All medical devices share a critical need regardless of their ... the supply chain. For medical devices traveling to cross border ...
Cached Medicine News:Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 2Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 3Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 4Health News:Barry Switzer to Receive Paul 'Bear' Bryant Lifetime Achievement Award 2Health News:Walgreens Pays U.S. $9.9 Million to Settle Medicaid Prescription Drug Allegations 2Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Medical Device Producers Express Interest in Purolator USA's Express Service and Customer Service 2
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: